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Abstract
Background: Clinical research into the effects of hormonal sup-
plementation has tended to focus on beneficial changes in anthro-
pometric measures. There are fewer data on long-term safety with 
extended hormonal supplementation.
Methods:  As part of a retrospective database survey, clinical out-
comes were tabulated among patients who received at least 1 year 
of testosterone and/or growth hormone (GH) supplementation. In 
patients who were treated for at least 2 years, changes in markers 
of glucose and lipid metabolism were analyzed with and without 
concomitant use of oral hypoglycemics and statins.
Results:  In 263 patients (mean age 56) treated for at least 2 years, 
the only statistically significant effect on markers of glucose me-
tabolism was an increase in glycated hemoglobin (still within nor-
mal limits) in patients receiving GH alone or in combination with 
testosterone but without oral hypoglycemics; with or without hypo-
glycemics, insulin levels showed no significant change. The only 
significant effects on markers of lipid metabolism were decreases 
in total cholesterol and low-density lipoprotein (LDL) in patients 
receiving combined testosterone and GH without statins. Decreases 
in LDL were significant in both the statin and non-statin groups; 
decreases in triglycerides were significant only in the statin group. 
In 531 patients treated for at least 1 year (mean age 54), the overall 
incidence of adverse clinical outcomes (prostate disease, diabetes, 
cardiovascular disease, cancer) was 1.3%.
Conclusions:  In this retrospective survey, extended testosterone 
and/or  GH  supplementation  did  not  adversely  affect  metabolic 
markers or clinical outcomes.
Keywords:  Safety; Testosterone; Growth hormone; Supplementa-
tion
Introduction
To date, most investigations of the use of testosterone and 
growth  hormone  (GH)  supplementation  have  focused  on 
anthropometric measures of body composition (lean mass, 
fat mass, bone mineral density [BMD]) and sexual function 
in hypogonadal men with clinically significant testosterone 
deficiency. In these patients, supplementation has produced 
beneficial effects not only on libido and sexual function [1] 
but also on lean and fat mass [2]. Furthermore, in a small 
open trial in eugonadal men with idiopathic osteoporosis, 
testosterone supplementation was reported to produce no-
table increases in BMD [3]. A review of the literature on this 
topic confirms that normalization of testosterone can lead to 
a more favorable anthropometric profile [4].
Although favorable changes in anthropometric measures 
may be associated with decreases in the risk of osteoporotic 
fracture, coronary artery disease and type-2 diabetes mel-
litus, these clinical outcomes are more difficult to demon-
strate, especially in the case of hormonal supplementation 
given  to  men  whose  testosterone  levels  are  near  normal 
rather than markedly deficient. In this setting, the clinical 
data are inconsistent. For example, in elderly men with low-
to-normal testosterone, a non-controlled trial (N = 122) of 
testosterone with and without growth hormone (GH) supple-
mentation reported increases in lean mass and decreases in 
fat mass accompanied by increases in muscle strength and 
aerobic endurance [5] whereas a placebo-controlled 6-month 
trial (N = 237) showed that supplementation produced the 
same pattern of favorable changes in lean and fat mass but 
no improvement in mobility or strength, or for that matter 
in  BMD  [6].  Testosterone  supplementation  in  androgen-
deficient women (often associated with hypopituitarism) is 
unusual, but the scant available data suggest that it may be 
beneficial in terms of sexual function, BMD, and lean mass, 
although adverse effects limit its clinical usefulness [7].
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Similarly, while there is no major dispute with GH sup-
plementation in individuals with documented GH deficiency, 
the benefit of supplementation in patients with near-normal 
GH levels remains controversial. In a small study of healthy 
elderly men participating in a program of resistance train-
ing, improvements in BMD were similar with and without 
adjunctive GH supplementation [8]. In contrast, adolescent 
males with idiopathic short stature and normal GH who re-
ceived supplementation showed increased lean mass and de-
creased fat mass, along with favorable effects on lipids, but 
unfavorable increases in fasting insulin levels and hepatic 
gluconeogenesis [9].
While the debate continues over the benefits of hormon-
al supplementation in patients with near-normal endogenous 
hormone levels, there has been even less certainty about the 
long-term safety of supplementation, especially in terms of 
metabolic, cardiovascular, and cancer risk. The present re-
port is a follow-up to a previously published database study 
showing that supplementation with testosterone, GH, or both 
had generally favorable effects on anthropometric measures 
in an outpatient population with low hormonal levels at base-
line [10]; the focus here is on safety outcomes in that popula-
tion.
Methods
This retrospective database study examined the records of 
patients treated at the Cenegenics Medical Institute (Las Ve-
gas, NV) during the period 1999–2006.
Table  1  summarizes  the  hormonal  regimens  used;  in 
addition to the use of testosterone and GH, other hormonal 
treatments were provided as needed to achieve normaliza-
tion of clinical and laboratory status, and all patients were 
advised to follow an exercise program and a low-glycemic 
diet.
Safety outcomes were assessed in 2 ways. Changes in 
metabolic markers were analyzed in patients who received 
hormonal  treatment  with  testosterone  (Tes),  GH,  or  both 
(Tes+GH) for at least 2 years. These assessments included 
markers of glucose metabolism in patients who were and 
were not taking concomitant oral hypoglycemic agents for 
hyperglycemia or diabetes, and markers of lipid metabolism 
in patients who were and were not taking concomitant statins 
(HMG-CoA reductase inhibitors) for hyperlipidemia. In ad-
dition, treatment-emergent cases of cardiovascular disease, 
diabetes, cancer, and prostate disease were tabulated in the 
larger group of patients who had received hormonal treat-
ment for at least 1 year.
Within-group mean changes from baseline to endpoint 
were assessed with a 2-sample t-test assuming equal vari-
ances. Between-group differences at a given time-point were 
assessed using the Mann-Whitney U test and the Kruskal-
Wallis  test.  For  correlations,  Pearson’s  test  was  used  for 
normally distributed data; otherwise, the Spearman rank test 
was used. All hypothesis tests were two-tailed, with statisti-
cal significance assessed at P < 0.05 with 95% confidence 
intervals. The statistical software used was SPSS 11.5 for 




In all, the records of 531 patients (89% males, mean age 54 
years) who received hormonal therapy for at least 1 year 
were reviewed. Of these, 24 patients received hormonal regi-
mens other than the 3 that were the focus of this study. Of the 
remaining 507 patients, 282 were in the Tes group (receiving 
Therapy (route) Goal Measurement
Testosterone, men (intramuscular)* Concentration representing 66th 
percentile (±12.5%) for 40-year-old men
Total 700 - 900 ng/dL,  
free 130 - 200 pg/mL
Testosterone, women (transdermal or 
sublingual)
Upper 33% of normal range for 
premenopausal women
Total 52-70 ng/dL
Human growth hormone 
(subcutaneous)
Upper 40% of normal range for age 39-
54 years
Rise of  ≥ 100% in insulin-like 
growth factor-1, to a maximum of 
360 ng/mL
Table 1. Hormonal Regimens
*Also includes use of human chorionic gonadotropin to increase endogenous testosterone production
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testosterone, human chorionic gonadotropin [hCG] to stimu-
late endogenous testosterone production, or both), 22 were 
in the GH group (receiving GH alone), and 203 were in the 
Tes+GH group (receiving GH in combination with testoster-
one and/or hCG). The records of 263 patients (mean age 56 
years) who were treated for at least 2 years were assessed 
for changes in metabolic markers; however, because of the 
retrospective nature of this study, the numbers of patients in 
whom initial and final data on metabolic markers were avail-
able varied with each outcome measure. The records of all 
531 patients who received hormonal treatment for at least 1 
year were assessed for new-onset cardiovascular disease, di-
abetes and prostate disease. The mean duration of hormonal 
supplementation was approximately 18 months.
Metabolic outcomes
Table 2 summarizes changes in markers of glucose metabo-
lism over the course of 2 years of treatment in patients who 
were not receiving concomitant treatment with oral hypogly-
cemic agents. The only statistically significant change was 
an increase from the initial assessment to the final assess-
ment in glycated hemoglobin (HbA1c) in the GH and Tes+GH 
groups; however, the final values (5.4% in both groups) were 
still well within normal limits.
Table 3 compares changes in insulin, as a representa-
tive marker of glucose metabolism during treatment with 
Tes+GH, in patients who did versus did not require concomi-
tant treatment with oral hypoglycemics (note that the data 
shown for the patients not taking oral hypoglycemics match 
the corresponding data for insulin effects in the Tes+GH 
group as shown in Table 2). Although the change from initial 
to final insulin values appears substantial in the group re-
ceiving concomitant hypoglycemics, the number of patients 
involved was too small (n = 10) to establish statistical sig-
nificance. However, the difference in insulin levels between 
groups was significant at the initial assessment and again at 
the final assessment, as would be expected between patients 
who do versus do not require therapy with oral hypoglyce-
mic agents.
Table 4 shows the changes in markers of lipid metabo-
lism in patients who were not receiving concomitant treat-
ment with statins. Levels of total cholesterol and low-density 
lipoprotein cholesterol (LDL) fell from the initial assessment 
to the final assessment in all treatment groups, but the chang-
es on both measures were statistically significant only in the 
Tes+GH group. Triglyceride levels also fell in all treatment 
groups; none of the changes was statistically significant, but 
the decrease approached significance in the Tes+GH group 
(P  =  0.058),  which  started  at  a  substantially  lower  mean 
Marker Treatment N Initial Value Final Value P value*
Fasting blood 
glucose (mg/dL)
Tes 39 90 93 0.549
GH 53 92 89 0.395
Tes+GH 82 90 92 0.177
Insulin (mIU/mL)
Tes 39 6.5 5.4 0.372
GH 51 5.7 7.3 0.137
Tes+GH 75 5.7 5.8 0.893
HbA1c (%) Tes 47 5.4 5.5 0.964
GH 57 5.1 5.4 < 0.001
Tes+GH 90 5.1 5.4 < 0.001
Table 2. Markers of Glucose Metabolism in Patients Not Receiving Concomitant Oral Hypoglycemic Agents
Tes: supplementation with testosterone (including use of human chorionic gonadotropin [hCG]); GH: supplementation 
with human growth hormone; Tes+GH: supplementation with testosterone and/or hCG, in combination with human growth 
hormone; HbA1c: glycated hemoglobin.
*Change from initial to final value within treatment group.
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value than the other groups (114 vs 134-136 mg/dL). High-
density lipoprotein cholesterol (HDL) levels showed little 
change over the course of 2 years of treatment.
Table 5 compares the changes in HDL, LDL, and tri-
glycerides during treatment with Tes+GH, in patients who 
did versus did not require concomitant treatment with statins. 
HDL showed little change in either group (with versus with-
out concomitant statins), and there were no significant be-
Marker Treatment: Tes+GH N Initial Value Final Value P value*
Insulin  
(mIU/mL)
With hypoglycemics 10 9.2 12.3 0.326
Without hypoglycemics
75 5.7 5.8 0.893
P value** < 0.005 < 0.001
Table 3. Marker of Glucose Metabolism In Patients Treated With Tes+GH With Versus Without Concomitant 
Oral Hypoglycemic Agents
Tes+GH: supplementation with testosterone and/or human chorionic gonadotropin, in combination with human growth 
hormone.
*Change from initial to final value within treatment group.
**Difference between treatment groups at initial assessment and at final assessment.
Marker Treatment N Initial Value Final Value P value*
Cholesterol (mg/dL) Tes 35 224 177 0.155
GH 7 204 198 0.759
Tes+GH 106 208 183 < 0.001
HDL (mg/dL) Tes 39 48 48 0.947
GH 7 47 56 0.286
Tes+GH 113 55 54 0.729
LDL (mg/dL) Tes 39 115 105 0.116
GH 7 125 115 0.597
Tes+GH 114 129 108 < 0.001
Triglycerides (mg/dL) Tes 39 134 121 0.483
GH 7 136 110 0.636
Tes+GH 114 114 97 0.058
Table 4. Markers of Lipid Metabolism in Patients Not Receiving Concomitant Statins
Tes: supplementation with testosterone (including use of human chorionic gonadotropin [hCG]); GH: supplementation with 
human growth hormone; Tes+GH: supplementation with testosterone and/or hCG, in combination with human growth hor-
mone; HDL: high-density lipoprotein cholesterol; LDL: low-density lipoprotein cholesterol.
*Change from initial to final value within treatment group.
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tween-group differences at the initial assessment or at the 
final assessment. In contrast, LDL showed highly significant 
decreases from initial to final assessment in both groups, 
but with no significant between-group differences at either 
assessment. Triglyceride  levels  decreased  in  both  groups, 
and the change from initial to final assessment, which only 
approached statistical significance in the non-statin group, 
was significant (P < 0.05) in the statin group. The greater 
magnitude of change in the statin group would be expected 
in patients receiving treatment for hyperlipidemia, and tri-
glyceride levels were in fact higher in the statin group than 
in the non-statin group at both the initial and the final assess-
ments. The between-group difference was significant only at 
the initial assessment, and the smaller difference at the final 
assessment reflects the results of statin therapy in lowering 
triglyceride levels.
Clinical outcomes
Among 531 patients who received at least 1 year of hormon-
al treatment (including 24 who were on regimens other than 
Tes, GH, or Tes+GH), 7 (1.3%) experienced new disease 
events during the study period. These treatment-emergent 
outcomes comprise 1 cardiac event, 1 case of hypertension, 
2 cases diabetes, and 3 cases of nonmalignant prostatic dis-
ease. There were no new cases of malignancy of any kind 
reported during the study period.
A total of 110 patients (20.7%) had pre-existing disease 
(including, for example, diabetes, which would account for 
the use of oral hypoglycemic drugs during hormonal sup-
plementation; or hyperlipidemia, which would account for 
the use of statins). Within this subgroup, 63 (57.3%) expe-
rienced no notable change in their pre-existing conditions, 




This retrospective database study showed that hormonal sup-
plementation with testosterone or GH or both, in conjunction 
with beneficial lifestyle changes in diet and exercise, was 
Marker Treatment: Tes+GH N Initial Value Final Value P value*
HDL (mg/dL)
With statins 35 52 53 0.844
Without statins
113 55 54 0.729
                                                                                P value**
0.373 0.719
LDL (mg/dL) With statins 35 137 97 < 0.001
Without statins
114 129 108 < 0.001
















114 114 97 0.058
                                                                                P value**
< 0.05 0.255
Tes+GH: supplementation with testosterone and/or human chorionic gonadotropin, in combination with human growth hor-
mone; HDL: high-density lipoprotein cholesterol; LDL: low-density lipoprotein cholesterol.
*Change from initial to final value within treatment group.
**Difference between treatment groups at initial assessment and at final assessment.
Table 5. Markers of Lipid Metabolism in Patients Treated With Tes+GH With Versus Without Concomitant Statins
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generally safe in terms of risk of adverse changes in meta-
bolic markers and adverse clinical outcomes.
Our  findings  must  be  placed  in  perspective  with  the 
extant literature on safety concerns with hormonal supple-
mentation. Looking first at testosterone, an obvious concern 
would be supplementation in men at increased risk for occur-
rence or recurrence of prostate cancer. The fact that castra-
tion has sometimes been employed to retard the advance of 
prostate cancer does not necessarily mean that testosterone 
supplementation in hypogonadal men increases their risk. 
Reviews on this subject dispute the assumption that risk is 
lower with depressed levels of testosterone [11, 12], and a 
recent comprehensive review finds no evidence that supple-
mentation to normalize testosterone levels increases the risk 
of prostate cancer [13]. On the other hand, a survey of urol-
ogy patients found a number of cases of new-onset prostate 
cancer that appeared within a few months to a few years of 
initiation of testosterone supplementation and were consid-
ered treatment-related [14]. Clearly, testosterone supplemen-
tation would not be appropriate in a patient in whom pros-
tatic cancer is suspected or documented [15, 16]. 
With respect to cancer risk in women who receive tes-
tosterone supplementation (e.g., for low sexual desire), a re-
view of the literature found inconsistent clinical data from 
flawed trials, and concluded that the available evidence does 
not clearly demonstrate any increased risk of breast cancer 
from adding testosterone to postmenopausal hormonal re-
placement therapy [17].
Diabetes risk may actually be reduced through testos-
terone  supplementation.  In  men  with  diabetes,  who  tend 
to show lower-than-normal levels of circulating androgen, 
supplementation improves glucose homeostasis, reduces vis-
ceral fat, and corrects insulin resistance [18]. Other compre-
hensive reviews conclude that testosterone supplementation 
can be beneficial in reducing the risks of diabetes and meta-
bolic syndrome in hypogonadal men [19, 20].
With  respect  to  cardiovascular  risk,  a  small  study 
showed no adverse increases in atherogenic lipids in 7 hy-
pogonadal men who completed 18 months of testosterone 
supplementation [21]. Similarly, no increased cardiovascular 
risk or harmful changes in atherogenic lipids were report-
ed in the previously mentioned study of 23 eugonadal men 
who showed increased BMD after 6 months of testosterone 
treatment for idiopathic osteoporosis [3]. Far from increas-
ing cardiovascular risk, testosterone supplementation may 
actually reduce risk in men (through beneficial effects on 
fibrinolysis, vascular endothelium, glucose metabolism, and 
coronary circulation), and potentially might also reduce the 
elevated cardiovascular risk seen in women following hys-
terectomy [22].
Turning to the smaller body of literature on GH, there 
are few reports relating to cancer risk. In a case report, co-
lon cancer developed in a patient at increased risk due to 
Crohn’s colitis, following use of GH as anti-aging therapy 
[23]. In contrast, there was no evidence of tumorogenicity in 
a preclinical report of GH administration in a mouse model 
[24]. In addition, a study in healthy volunteers found that GH 
supplementation increased the antitumor activity of natural 
killer cells [25].
In another preclinical model involving mice fed a high-
fat diet, low-dose GH supplementation seemed to inhibit the 
expression of cellular changes associated with insulin resis-
tance [26], suggesting a possible protective effect. 
A small study in 7 fit men with normal hormone lev-
els showed that GH supplementation led to dose-related de-
creases in total cholesterol [27]. A more definitive study in 
obese men and women found that GH produced a modest 
reduction in body fat had no significant effect on markers of 
adiposity (leptin, adiponectin, and C-reactive protein); nev-
ertheless, no worsening in metabolic markers was reported 
[28]. In a preclinical model of congestive heart failure, short-
term use of GH improved left ventricular function through 
favorable effects on myocardial remodeling and contractility 
[29].
Not  surprisingly,  the  overall  conclusion  from  the  lit-
erature  is  that  whereas  the  medical  benefits  of  hormonal 
supplementation can be clearly documented in hypogonadal 
patients, the proper role of supplementation is, at this time, 
harder to define in patients who are not clearly hypogonadal 
[30]. Such discrepancies as may exist between our study and 
previously published reports do not seem to involve directly 
contradictory findings.
Next, it is necessary to place the current findings in per-
spective with risks in the general population. The annual 
incidence  of  coronary  heart  disease  is  estimated  at  0.3% 
among males in the age range 35-44 years; the incidence 
among women is somewhat lower and the overall incidence 
of cardiovascular disease of any kind would be higher [31]. 
Our study population might be considered at greater risk than 
the reference population on the basis of older age, and at 
slightly lower risk because it included women (11% of the 
population). Among  531  patients  who  received  hormonal 
supplementation for at least 1 year and for a mean period of 
approximately 18 months, only 1 treatment-emergent case 
of cardiac disease was reported (incidence 0.2%). Even if 
the single case of treatment-emergent hypertension is also 
included in this category, the incidence of new-onset cardio-
vascular disease in our population, 2 cases among 531 pa-
tients (0.4%), is no higher than the incidence in the general 
population.
Similarly, the incidence of treatment-emergent diabetes 
in our population may be compared with the annual incidence 
of diabetes in the general population, which is estimated at 
0.7% in people over age 20 years [32]. The age range of our 
study population lies within that reference range, and the 2 
cases of new-onset diabetes we report represent an incidence 
of 0.4%, which, again, is certainly no higher than the inci-
dence in the general population.
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Finally, with respect to cancer risk, there were no cases 
of new-onset malignancy in our study. By contrast, within 
the general population, the annual incidence is approximate-
ly 0.4% (higher in men, lower in women) for all forms of 
cancer combined, excluding common basal and squamous 
cell carcinomas of the skin [33].
Although the incidence of these adverse outcomes might 
be expected to be higher in this more closely monitored pop-
ulation than in the general population, the reported incidence 
rates of cardiovascular disease, diabetes, and cancer over the 
course of at least 1 year of hormonal supplementation were, 
in fact, no higher and possibly lower than the 1-year inci-
dence rates for these conditions in the general population. 
Indeed, the overall incidence of adverse clinical outcomes (7 
among 531 patients, or 1.3%) is too small for any meaning-
ful assessment of risk by treatment group.
However, comparisons of risk in our study population 
versus the general population must be interpreted with cau-
tion. For example, the fact that the incidence of cancer was 
zero in our population in no way supports a claim of de-
creased  risk  with  hormonal  supplementation.  What  these 
comparisons demonstrate is that long-term hormonal supple-
mentation was not associated with any discernible increased 
risk. 
The main limitations of this study are its design as a 
retrospective database survey and the lack of stratification 
of outcome data by clinical and demographic variables. The 
current findings do not distinguish between results in young-
er versus older patients, in male versus female patients, or in 
patients with different levels of endogenous hormones and 
different anthropometric measures of body composition at 
baseline. Similarly, among patients taking concomitant oral 
hypoglycemic or statin therapy, there is no comparison of 
changes in metabolic markers in those taking lower versus 
higher doses of concomitant medications for milder versus 
more severe pre-existing abnormalities in glucose or lipid 
metabolism. Furthermore, we cannot determine to what de-
gree the healthful diet-and-exercise regimen may have mod-
ulated changes in metabolic markers and the risk of adverse 
clinical outcomes, or to what degree the reported treatment-
emergent adverse clinical outcomes were treatment-related, 
that is, which events were possibly or probably attributable 
to hormonal supplementation. On the other hand, such analy-
ses might not have yielded meaningful distinctions between 
subgroups given the low overall rate of adverse outcomes. 
Another  limitation  is  that  the  number  of  patients  treated 
with GH alone (n = 22) was much smaller than the numbers 
treated with testosterone (n = 282) or combined testosterone 
and GH (n = 203); therefore, the outcomes reported for GH 
cannot be considered as robust as the outcomes reported for 
the other regimens. Notwithstanding these limitations, our 
results, showing no evidence of increased clinical risk after 
1 to 2 years of hormonal supplementation, may be relevant in 
light of the relative paucity of long-term data on safety out-
comes after extended treatment with testosterone and GH.
Conclusions
In this retrospective database survey, long-term hormonal 
supplementation  with  testosterone  and/or  human  growth 
hormone was not associated with adverse effects on markers 
of glucose or lipid metabolism, and did not incur increased 
risk of adverse clinical outcomes relating to new onset of 
diabetes, cardiovascular disease, or cancer.
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